Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15877830 | 1.00 | KMT2A (0.51) | KMT2ANPC1RAB9ABRD4BTK | |
| SCHEMBL15894489 | 1.00 | KMT2A (0.51) | KMT2ANPC1RAB9ABRD4BTK | |
| SCHEMBL15894492 | 0.91 | KMT2A (0.52) | KMT2ANPC1RAB9ABRD4BTK | |
| SCHEMBL15877677 | 0.91 | KMT2A (0.52) | KMT2ANPC1RAB9ABRD4BTK | |
| SCHEMBL15877675 | 0.91 | KMT2A (0.52) | KMT2ANPC1RAB9ABRD4BTK | |
| SCHEMBL17184777 | 0.83 | BRD4 (0.62) | BRD4POLBGAA | |
| SCHEMBL23236621 | 0.80 | POLB (0.57) | KMT2ANPC1RAB9AGFERMEN1 | |
| SCHEMBL15877734 | 0.80 | POLB (0.57) | KMT2ANPC1RAB9AGFERMEN1 | |
| SCHEMBL15878151 | 0.80 | POLB (0.57) | KMT2ANPC1RAB9AGFERMEN1 | |
| SCHEMBL15878150 | 0.80 | POLB (0.57) | KMT2ANPC1RAB9AGFERMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2948458-B1 | BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2019-05-01 | — | — | EP | disclosed |
| US-9481682-B2 | Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20150353570-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| EP-2948458-A1 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-12-02 | — | — | EP | disclosed |
| WO-2014114185-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014113932-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-07-31 | — | — | WO | disclosed |
| US-20140206681-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. | 2014-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206681-A1 | BTK INHIBITORS | BTK, SYK, LYN | KMT2A 1175/4885NPC1 2645/4885RAB9A 1837/4885 |
| US-20150353570-A1 | BTK INHIBITORS | BTK, SYK, LYN | KMT2A 1175/4885NPC1 2645/4885RAB9A 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.